Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Unknown 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 6Lymphoid 4Thoracic 1Plasma cell 1Gastrointestinal 1

Conditions

Stomach Neoplasms 1Pancreatic Neoplasms 1Colorectal Neoplasms 1Carcinoma, Non-Small-Cell Lung 1Carcinoma, Hepatocellular 1

Interventions

Carboplatin 132Cisplatin 129Pemetrexed 114Docetaxel 81Drug Therapy 62Gefitinib 57anlotinib 55Gemcitabine 55Erlotinib Hydrochloride 55Radiotherapy 48Bevacizumab 48pembrolizumab 47Paclitaxel 47Etoposide 44apatinib 42icotinib 41camrelizumab 39osimertinib 36Nivolumab 33Vinorelbine 31Radiosurgery 30sintilimab 29durvalumab 25aumolertinib 25endostar protein 24atezolizumab 22Endostatins 22toripalimab 19Blood Specimen Collection 19tislelizumab 18

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Unknown × Sensitivity and Specificity × Thoracic × Clear all
NCT02839954 2016-12-06

CAR-pNK Cell Immunotherapy in MUC1 Positive Relapsed or Refractory Solid Tumor

PersonGen BioTherapeutics (Suzhou) Co., Ltd.

Phase 1/2 Unknown
10 enrolled
GastrointestinalThoracic

Carcinoma, Non-Small-Cell Lung, Carcinoma, Hepatocellular, Pancreatic Neoplasms, Stomach Neoplasms, Colorectal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡